Alps Advisors News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alps advisors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alps Advisors Today - Breaking & Trending Today

Arthur A. Levin Sells 40,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) Stock

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) Director Arthur A. Levin sold 40,000 shares of Avidity Biosciences stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $35.07, for a total transaction of $1,402,800.00. Following the completion of the transaction, the director now directly owns […] ....

Los Angeles , United States , Arthura Levin , Los Angeles Capital Management , Proshare Advisors , Cantor Fitzgerald , Avidity Biosciences Company Profile , Avidity Biosciences Inc , Alps Advisors Inc , Board Of Administration Florida Retirement System , Needham Company , Hennion Walsh Asset Management Inc , Securities Exchange Commission , Avidity Biosciences , Get Free Report , Director Arthur , Exchange Commission , Chardan Capital , Florida Retirement System , Angeles Capital Management , Walsh Asset Management , Share Advisors , Alps Advisors , Avidity Biosciences Daily ,

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Analysts

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month […] ....

Switzerland General , Arie Belldegrun , Piper Sandler , Jpmorgan Chase Co , Securities Exchange Commission , Royal Bank , Sg Americas Securities , Allogene Therapeutics Inc , Citigroup Inc , Swiss National Bank , Alps Advisors Inc , Allogene Therapeutics , Get Free Report , Director Arie Belldegrun , Exchange Commission , National Bank , Alps Advisors , Get Free , Allogene Therapeutics Daily ,

3D Systems Co. (NYSE:DDD) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. decreased its stake in 3D Systems Co. (NYSE:DDD – Free Report) by 3.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 695,101 shares of the 3D printing company’s stock after selling 23,087 shares during the quarter. Principal […] ....

Asia Pacific , Caxton Associates , D Systems Corporation , Principal Financial Group Inc , Campbell Co Investment Adviser , Securities Exchange Commission , Investment Management , Alps Advisors Inc , Cantor Fitzgerald , Silverberg Bernstein Capital Management , 3d Systems Co , Principal Financial Group , Free Report , Financial Group , Bernstein Capital Management , Alps Advisors , Systems Stock , Get Free Report , Systems Corporation , Middle East , Systems Daily ,

Wedbush Reiterates "Outperform" Rating for Aerovate Therapeutics (NASDAQ:AVTE)

Wedbush restated their outperform rating on shares of Aerovate Therapeutics (NASDAQ:AVTE – Free Report) in a research report report published on Wednesday, Benzinga reports. The brokerage currently has a $41.00 price target on the stock. AVTE has been the subject of a number of other reports. Wells Fargo & Company reissued an overweight rating and […] ....

United States , Georgea Eldridge , Hunter Gillies , Eventide Asset Management , Jefferies Financial Group , Ikarian Capital , Aerovate Therapeutics Inc , Wells Fargo Company , Vanguard Group Inc , Alps Advisors Inc , Aerovate Therapeutics , Free Report , Financial Group , Therapeutics Stock Down , Get Free Report , Asset Management , Point Capital , Alps Advisors , Aerovate Therapeutics Daily ,

Truist Financial Reiterates Buy Rating for Allogene Therapeutics (NASDAQ:ALLO)

Truist Financial reiterated their buy rating on shares of Allogene Therapeutics (NASDAQ:ALLO – Free Report) in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $17.00 price target on the stock. A number of other analysts also recently weighed in on ALLO. Royal Bank of Canada reiterated an outperform rating […] ....

Switzerland General , Stifel Nicolaus , Citigroup Inc , Allogene Therapeutics Inc , Jpmorgan Chase Co , Alps Advisors Inc , Sg Americas Securities , Royal Bank , Swiss National Bank , Truist Financial , Allogene Therapeutics , Free Report , Moderate Buy , Therapeutics Stock Down , Get Free Report , National Bank , Alps Advisors , Allogene Therapeutics Daily ,